Arbutus

mRNA LNP Patent Wars Escalate: Arbutus, Sanofi Challenge Pfizer, Moderna; New Therapies Advance

Arbutus and Sanofi are escalating mRNA lipid nanoparticle (LNP) patent disputes against Pfizer, BioNTech, and Moderna across the U.S., Europe, and Canada, impacting market access and IP strategies. Concurrently, InnoCare's soficitinib and Insmed's TPIP show promising clinical trial results, while Argenx and Chai Discovery forge AI-driven antibody discovery partnerships, signaling shifts in R&D investment and future therapeutic pipelines.